1-5 of 5
Abigail Evans
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Correction: Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT)

John F.R. Robertson, Robert E. Coleman, Kwok-Leung Cheung, Abigail Evans, Chris Holcombe, Anthony Skene, Daniel Rea, Samreen Ahmed, Ali Jahan, Kieran Horgan, Petra Rauchhaus, Roberta Littleford, S.Y. Amy Cheung, Marie Cullberg, Elza C. de Bruin, Loumpiana Koulai, Justin P.O. Lindemann, Martin Pass, Paul Rugman, Gaia Schiavon, Rahul Deb, Pauline Finlay, Andrew Foxley, Julia M.W. Gee
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (24): 5469.
https://doi.org/10.1158/1078-0432.CCR-22-3568
Published: 15 December 2022
View article titled, Correction: Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER<sup>+</sup> Invasive Breast Cancer (STAKT)
Open the PDF for Correction: Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER<sup>+</sup> Invasive Breast Cancer (STAKT) in another window
Journal Articles

Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results

Nigel Bundred, Nuria Porta, Adrian Murray Brunt, Angela Cramer, Andrew Hanby, Abeer M. Shaaban, Emad A. Rakha, Anne Armstrong, Ramsey I. Cutress, David Dodwell, Marie A. Emson, Abigail Evans, Sue M. Hartup, Kieran Horgan, Sarah E. Miller, Stuart A. McIntosh, James P. Morden, Jay Naik, Sankaran Narayanan, Jane Ooi, Anthony I. Skene, David A. Cameron, Judith M. Bliss
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1323–1334.
https://doi.org/10.1158/1078-0432.CCR-21-3177
Published: 01 April 2022
View article titled, Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Open the PDF for Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results in another window
Includes: Supplementary data
Journal Articles

A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2− Primary Breast Cancer

John F.R. Robertson, Abigail Evans, Stephan Henschen, Cliona C. Kirwan, Ali Jahan, Laura M. Kenny, J. Michael Dixon, Peter Schmid, Ashutosh Kothari, Omar Mohamed, Peter A. Fasching, Kwok-Leung Cheung, Rachel Wuerstlein, Danielle Carroll, Teresa Klinowska, Justin P.O. Lindemann, Alexander MacDonald, Richard Mather, Rhiannon Maudsley, Michele Moschetta, Myria Nikolaou, Martine P. Roudier, Tinnu Sarvotham, Gaia Schiavon, Diansong Zhou, Li Zhou, Nadia Harbeck
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (16): 4242–4249.
https://doi.org/10.1158/1078-0432.CCR-19-3387
Published: 14 August 2020
View article titled, A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER<sup>+</sup> HER2<sup>−</sup> Primary Breast Cancer
Open the PDF for A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER<sup>+</sup> HER2<sup>−</sup> Primary Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT)

John F.R. Robertson, Robert E. Coleman, Kwok-Leung Cheung, Abigail Evans, Chris Holcombe, Anthony Skene, Daniel Rea, Samreen Ahmed, Ali Jahan, Kieran Horgan, Petra Rauchhaus, Roberta Littleford, S.Y. Amy Cheung, Marie Cullberg, Elza C. de Bruin, Loumpiana Koulai, Justin P.O. Lindemann, Martin Pass, Paul Rugman, Gaia Schiavon, Rahul Deb, Pauline Finlay, Andrew Foxley, Julia M.W. Gee
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (7): 1574–1585.
https://doi.org/10.1158/1078-0432.CCR-19-3053
Published: 01 April 2020
View article titled, Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER<sup>+</sup> Invasive Breast Cancer (STAKT)
Open the PDF for Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER<sup>+</sup> Invasive Breast Cancer (STAKT) in another window
Includes: Supplementary data
Journal Articles

Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)

Alexandra Leary, Abigail Evans, Stephen R.D. Johnston, Roger A'Hern, Judith M. Bliss, Rashmita Sahoo, Simone Detre, Benjamin P. Haynes, Margaret Hills, Catherine Harper-Wynne, Nigel Bundred, Gill Coombes, Ian Smith, Mitch Dowsett
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (13): 2932–2940.
https://doi.org/10.1158/1078-0432.CCR-14-1428
Published: 30 June 2015
View article titled, Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
Open the PDF for Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039) in another window
Includes: Supplementary data